Incretin-Based Therapies Versus Bariatric and Metabolic Surgery for Obesity and Type 2 Diabetes Mellitus: A Head-to-Head Systematic Review of Glycaemic, Cardiovascular, Hepatic, Weight, and Quality-of-Life Outcomes
- Design
- Systematic review · Mixed outcome
- Match to healthy normal-weight adults aged 55–75
- Different population[Auto] Synthesis of studies conducted predominantly in people with obesity/overweight.
- Could weight loss explain it?
- Possibly[Auto] Participants had obesity and/or type 2 diabetes and the abstract does not separate direct drug effects from weight loss or glycaemic improvement.
- Study tier
- Study tier 2[Auto] Systematic review/meta-analysis of randomized trials (auto-provisional; heterogeneity and included-study quality not assessed).
- Assessment
- Version 1 · automatic, not yet reviewed by a person · Sep 13, 2026
Study facts come from the paper. Population match, weight-loss explanation and study tier are our judgments, made against the reference group of healthy normal-weight adults aged 55–75.
[Auto, unreviewed; last sentences of abstract] Complementary and sequential use - incretins as a bridge to or adjunct following surgery - warrants prospective evaluation. Guidelines should position BMS as a first-line option in appropriate candidates.
01Findings
What the study reported
- Drugs
- Semaglutide, Tirzepatide
- Dose
- 15 mg
- Comparator
- Bariatric and Metabolic Surgery
- Primary outcome
- Not extracted
- Effect
- Not extracted
- 95% confidence interval
- Not extracted
- Follow-up
- 72 weeks
- Adverse events
- Not extracted
- Limitations
- Auto-classified from abstract only; effect estimates, adverse events and limitations not extracted. Requires manual review.
Who was studied
- Obesity status
- obesity/overweight present (all or most)
- Diabetes status
- diabetes mentioned
- Baseline condition
- MASH / MASLD
Study quality details
- Study design
- Systematic review
- Sample size
- not extracted
- Randomization
- n/a
- Blinding
- not stated
- Comparator
- not stated
- Follow up duration
- 72 weeks
- Outcome type
- mixed
- Replication
- not assessed (auto)
- Consistency with other evidence
- not assessed (auto)
- Population applicability
- INDIRECT
- Statistical precision
- CI reported: 95% CI 0
- Risk of bias
- not assessed (auto)
- Funding conflicts
- unclear
- Peer review status
- yes
02Funding
Funding and conflicts
- Funding
- not reported in abstract
- Industry funded
- Unclear
- Manufacturer
- None identified
- Sponsor role
- not reported in abstract
- Author conflicts
- Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.
- Independent replication
- unknown
Funding is shown on every study and never used to score it.
04Source
The source, as retrieved
Abstract
Once-weekly glucagon-like peptide-1 receptor agonists (GLP-1 RAs) such as semaglutide and the dual glucose-dependent insulinotropic polypeptide (GIP)/GLP-1 co-agonist tirzepatide have transformed non-surgical management of obesity and type 2 diabetes mellitus (T2DM), producing unprecedented pharmacological weight loss and cardiovascular mortality benefit. Bariatric and metabolic surgery (BMS) remains the most effective intervention for sustained weight reduction and T2DM remission. A systematic outcome-by-outcome comparison of these paradigms has not previously been synthesised. We conducted a PRISMA 2020-compliant systematic review of randomised controlled trials (RCTs) and high-quality matched observational studies (January 2014-April 2026) comparing incretin-based therapies with BMS in adults with obesity and T2DM. Primary outcomes were T2DM remission, weight reduction, major adverse cardiovascular events (MACE) and all-cause mortality, non-alcoholic steatohepatitis (NASH) resolution, and quality of life (QoL). Secondary outcomes included HbA1c, lipids, blood pressure, renal endpoints, and safety. Risk of bias was assessed using the Cochrane Risk of Bias 2 (RoB 2) and Newcastle-Ottawa Scale; certainty was graded using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach. Fourteen studies met inclusion criteria (eight RCTs, six matched cohorts; N=25,566). BMS achieved superior T2DM remission (23-70% vs. 0%), greater sustained five-year weight loss (25-32% vs. 14.9-20.9% with semaglutide/tirzepatide, with significant pharmacological weight regain upon discontinuation), and lower MACE risk (pooled RR 0.48, 95% CI 0.33-0.72 vs. GLP-1 RAs; P<0.001). BMS was also superior for NASH histological resolution (56-70% vs. 59% with semaglutide) and QoL. Incretin therapies produced clinically meaningful cardiometabolic improvements with favourable safety profiles dominated by transient gastrointestinal events. Tirzepatide 15 mg approached but did not match sleeve gastrectomy weight-loss benchmarks at 72 weeks. BMS demonstrates superiority across all five primary outcome domains in patients with obesity and established T2DM. Incretin therapies remain essential for those who decline, defer, or are contraindicated for surgery. Complementary and sequential use - incretins as a bridge to or adjunct following surgery - warrants prospective evaluation. Guidelines should position BMS as a first-line option in appropriate candidates.